Targeted therapy of breast cancer
	    		
		   		
		   			
		   		
	    	
    	 
    	10.3760/cma.j.issn.1673-422X.2016.04.019
   		
        
        	
        		- VernacularTitle:乳腺癌的靶向治疗
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Cheng ZHANG
			        		
			        		;
		        		
		        		
		        		
			        		Zhengquan ZHANG
			        		
			        		;
		        		
		        		
		        		
			        		Deyuan FU
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Journal Article
 
        	
        	
        		- Keywords:
        			
	        			
	        				
	        				
			        		
				        		Breast neoplasms;
			        		
			        		
			        		
				        		Molecular targeted therapy
			        		
			        		
	        			
        			
        		
 
        	
            
            
            	- From:
	            		
	            			Journal of International Oncology
	            		
	            		 2016;43(4):309-311
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	Targeted therapies of breast cancer offer a possibility of effective and individualized therapy based on the molecular profile of the tumor.Currently there are three main types of targeted therapeutic drugs for breast cancer,the first category is the monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) including trastuzumab,pertuzumab,lapatinib,T-DM1.The second is targeting VEGF such as bevacizumab.The last one everolimus is a mammalian target of rapamycin (mTOR) inhibitors.A number of trials suggest that the addition of targeted therapy to chemotherapy or endocrine therapy significantly improved PFS and OS in patients with breast cancer.